The biotechnology sector is attracting significant investment as it deals with a myriad of transformative breakthroughs in agriculture as well as healthcare applications. Modern applications such as gene editing, therapies, etc., are enabling highly effective, driving prominent commercial potential. According to statistics published by the International Trade Administration in the U.S., in 2022, more than USD 25 billion in biopharmaceutical exports were from foreign-owned companies operating in the country. Moreover, data published by India Barnd Equity Foundation, by September 2025, the country has witnessed the establishment of more than 11,000 biotech startups in biotech, showcasing a flourishing innovation ecosystem across various segments.
Indian Biotechnology Industry Valuation (USD Billion)
Source: IBEF
Latest trends in biotechnology
Gene editing and CRISPR technologies
Investors are allocating capital into CRISPR technologies, as these novel technologies illustrate a paradigm leap in innovations with broad commercial viability. CRISPR can render scalable and low-cost modifications, which places it as a core technology instead of a niche solution. Also, the CRISPR offers applications across industrial biotechnology, agriculture, and biomanufacturing, which expand commercialization. According to the Kaiser Foundation Health, annual spending on gene therapy in the U.S. by 2026 would be USD 25.3 billion. Additionally, these biological innovations are significantly amalgamated with digital tools such as data analytics to foster swift breeding cycles and high-quality precision farming. Trends such as AI-enabled drug discovery and adoption of next-generation therapeutics are placing biotechnology as a critical enabler of resource-efficient and technology-driven systems.
Bioinformatics and AI-enabled drug discovery
Various investors are betting on bioinformatics as well as AI tools in drug discovery to speed up target identification. The inclusion of AI can unveil crucial information from vast biological datasets. There are advances in proteomics and genomics that have created data volumes that are impossible to decipher manually. AI renders a competitive moat, and the companies that are investing early can develop platforms that can scale across a myriad of therapeutic areas. These factors have raised big tech collaborations, as various incumbents are seeking to diversify innovations. For instance, in 2023, Insilico Medicine utilized generative AI to design and discover drugs for idiopathic pulmonary fibrosis (IPF). With such clinical progress, investors are showing confidence in the convergence of AI and life sciences.
mRNA and next-generation vaccine platforms
The inclusion of mRNA and next-generation vaccine manufacturing platforms is garnering significant investment as they have proven to be multi-indication therapeutic platforms. mRNA fosters digital first design allowing companies swiftly move from sequence identification to clinical development. This speedy development is significantly valuable with the widening applications in rare genetic diseases and developing personalized cancer vaccines. Investors are viewing mRNA as a reusable platform technology that can improve long-term pipeline productivity. According to the World Health Organization mRNA technology transfer programme is moving into Phase 2.0 for 2026-2030. The plan is focusing on enabling commercially viable mRNA vaccines for influenza, HIV, and malaria in various regions such as Latin America and Asia. Overall, these developments highlight the surge in investor confidence in next-generation vaccine platforms and as long-term growth pillars in biopharmaceutical innovation.
Rising usage of biotechnology in carbon capture biology
Carbon capture biology, though biotechnology is attracting significant investment as companies are seeking science-led solutions for decarbonization. The fabrication of engineered algae and enzymes is capable of biologically capturing and converting carbon dioxide into biochemicals, rendering a pathway to lower emissions. Also, water treatment biotechnology is gaining significant traction as industries are facing stringent environmental compliance needs. The inclusion of biofilms and microbial consortia can effectively eliminate hydrocarbons from soil and wastewater. According to research conducted by Cambridge University in 2025, Chlorella microalgae was noted for its ability to fix CO2 while treating wastewater, sequestering 183 t CO2 per 100 t algal biomass.
What We Do
Rising concerns for inflation, fear of recession, contracting revenues, shrinking profit margins, and growing cost pressure on logistics and supply chain has posed a profound stress test for every business organizations globally. We’re helping our clients by delivering integrated solutions based on thorough research, benchmarking, analysis, and strategic discernment to help businesses overcome these challenges and unearth hidden opportunities for sustainable growth and value creation over the coming years.
We have been a pedestal for our clients to embark on a journey towards success.
